Vidcast:  https://www.instagram.com/drhowardsmithreports/reel/DHWmcgnMxf3/

Two-thirds of children wearing peanut skin patches were safely desensitized to this common kid allergen.  Pediatric allergists at the University of Colorado followed 298 children 4 to 11 years of age in their phase 3 study of so-called epicutaneous  immunotherapy.

The Viaskin Peanut Patch delivers 250 ug of peanut protein, and over 90% of the children were able to wear the patch for the entire 5 year study period.  The children’s level of tolerance to a stiff peanut protein challenge of 1000 ug rose gradually as they wore the patch.  After one year, one-third of the children tolerated this challenge but that figure tripled by the study’s completion.

The Viaskin Patch still awaits FDA approval, but it represents a non-invasive, readily tolerated option to the oral route for peanut desensitization. 

https://www.medscape.com/viewarticle/epicutaneous-immunotherapy-future-peanut-allergy-treatment-2025a10005s3

#peanut #allergy #patch #desensitization #immunotherapy #viaskin